MD Anderson, Theraclone launch OncoResponse

The University of Texas MD Anderson Cancer Center (Houston, Texas) and Theraclone Sciences Inc. (Seattle, Wash.) jointly launched cancer immunotherapy company OncoResponse Inc. (Houston, Texas). The newco closed a $9.5 million series A round co-led by Arch Venture Partners; Canaan Partners; and MD Anderson. Rice University and Alexandria Real Estate Equities also participated.

OncoResponse will use Theraclone's I-STAR antibody discovery platform to identify antibodies from exceptional responders to immunotherapy. MD Anderson will provide the company with samples and physiologic, prognostic and genotypic data from exceptional responders. ...